Abstract. Prostate cancer antigen 3 (PCA3) is a non-coding RNA fragment that is overexpressed in prostate cancer cells. However, the clinical applications of PCA3 are highly limited due to the instability of RNA and the lack of reliable and efficient RNA extraction and purification methods. Thus, in the present study, we compared three different methods of RNA extraction to further confirm the higher yield of commercial magnetic beads with poly-T functionalization and a capturer strand. The current protocols for RNA extraction of i) the phenol-chloroform method, ii) the affinity column method and iii) magnetic beads with poly-T functionalization and a capturer strand were applied separately for RNA extraction in urine samples. Reverse transcription-quantitative polymerase chain reaction was performed to evaluate the yield of the three methods of RNA extraction. Furthermore, 52 urine samples after prostate massage from patients suspected of a diagnosis of prostate cancer were collected. The Mag-Cap method and RT-PCR were applied to obtain the PCA3 score. The clinical value of the PCA3 score was investigated by comparison with the pathology of the prostate biopsy. The yield of the Mag-Cap method was higher than that of the phenol-chloroform method and commercial kits. Thirty-four patients were pathologically diagnosed with prostate cancer and 18 with benign prostatic hyperplasia (BPH). It was confirmed that the median PCA3 score was higher among the prostate cancer patients than those with benign disease (53.5 vs. 17, p=0.000). A sensitivity of 82.4% and a specificity of 77.8% were obtained when the cut-off value for the PCA3 score was 28.5. The Mag-Cap method was found to be more efficient for RNA extraction. The urinary PCA3 score is a promising method for prostate cancer screening, detection and diagnosis, and has the potential to reduce unnecessary prostate biopsies.
Introduction
Prostate cancer remains challenging to clinical oncologists due to the fact that it has the highest incidence and second highest mortality rate among all cancer types for males in developed countries (1) (2) (3) . In China, the incidence of prostate cancer is only lower than malignant tumors of the lung, stomach, esophagus, colon/rectum and liver (4) . However, the incidence rate of prostate cancer is rising significantly. It is expected that the incidence of prostate cancer in China will reach 40/100,000 males in 2020, with annual new cases estimated at 350,000.
Prostate cancer is among the few cancers that can be screened and detected at an early stage (5) . Prostate-specific antigen (PSA) has been widely accepted for prostate cancer screening (6) (7) (8) (9) . As a protein secreted only inside the prostate glands (10) , its presence in blood/serum is trivial for healthy subjects. An abnormally high serum PSA level is evidence of a prostate lesion or a disorder such as prostate cancer. However, the application of PSA for prostate cancer diagnosis remains controversial. The debates are mainly focused on the poor sensitivity and specificity and the resulting over-diagnosis (11) .
An alternative for PSA screening is prostate cancer antigen 3 (PCA3). PCA3 is a non-coding RNA expressed inside the prostate gland (12) . Overexpression of PCA3 is common among prostate cancer patients (13) (14) (15) (16) (17) . PCA3 is reported to be more cancer-specific, and thus a promising nextgeneration marker for prostate cancer screening (18) (19) (20) (21) . With higher specificity than PSA, PCA3 is expected to play more important roles in clinical practice such as prostate cancer screening, grading and recurrence monitoring (22 stability and lack of a purification method from complex matrix. Nanotechnology has highly influenced biomedical research and clinical laboratory practice (23) (24) (25) . Magnetic beads are nano-sized or micro-sized ferromagnetic iron oxide particles. Functionalized magnetic beads coated with antibodies or oligonucleotides have been widely used for the purification, extraction and detection of biomolecules (26, 27) . We herein report a general method for RNA extraction based on magnetic beads and capturer strands, and its application for prostate cancer screening and diagnosis. As shown in Fig. 1 , magnetic beads covalently conjugated to poly-T strands were incubated with the capturing strand (capturer) which involves poly-A and a sequence that is complementary to part of the target sequence (e.g., PSA or PCA3). The capturer is then immobilized on the magnetic beads through A-T pairing. The beads are incubated with the sample, through which the target sequences are captured by hybridization. Finally the beads with target immobilization are precipitated by magnetic attraction and carefully washed so that the interference sequences are removed with washing buffer. The target strand is eluted by heat-denaturation at an appropriate temperature.
Patients and methods
Patients and sample acquisition. Prostate cancer cell line 22RV1 (Institute of Biochemistry and Cell Biology CAS, cat. TCHu100) was cultured in RPMI-1640 media that contained bovine serum (100 ml/l) (both from Hyclone) and penicillin (100 U/ml; Sigma-Aldrich) at 37˚C and with 50 ml/l CO 2 . Female urine samples were collected in an RNAse-free vial. Patients enrolled in the study included 34 pathologically diagnosed primary prostate cancer patients and 18 patients with benign prostatic hyperplasia (BPH). All patients were enrolled at Peking Union Medical College Hospital. For males, urine samples of 20-30 ml were collected after prostate massage (28) . Urine samples from both male and female participants were aliquoted; an aliquot of 5 ml urine was mixed with storage buffer (100 mM Tris-HCl, 500 mM LiCl, 10 mM EDTA, pH 7.5, 1% lithium dodecyl sulfate, 5 mM dithiothreitol) (all chemicals from Sigma-Aldrich) in a 1:1 ratio. RNA extraction occurred within 4 h after sample collection. Urine samples were stored at 4˚C for short term storage or at -80˚C for long term storage.
The study was approved by the Ethics Committee of Peking Union Medical College Hospital. All participants provided their written informed consent to participate in this study.
Phenol-chloroform extraction of RNA. The untreated female urine sample (0.5 ml with the addition of 10 4 22RV1 cells) was centrifuged for 5 min (3,500 rpm, 4˚C); the supernatant was discarded. The sample was mixed with 1 ml TRIzol (Life Technologies) and incubated for 5 min at ambient temperature. The mixture was added with 200 µl chloroform (Sigma-Aldrich), vortexed for 15 sec and incubated for 3 min at ambient temperature. The mixture was centrifuged for 15 min (13,000 rpm, 4˚C). The aqueous layer was transferred to an RNAse-free vial and mixed with isopropanol of the same volume. The mixture was gently shaken and incubated for 10 min. The mixture was centrifuged for 15 min (13,000 rpm, 4˚C), the supernatant was discarded, 50 µl of 70% ethanol was added and the vial was gently shaken. The mixture was centrifuged for another 5 min (13,000 rpm, 4˚C), and the supernatant was discarded. The vial was dried with a vacuum and the vial was rehydrated with 500 µl DEPC-treated RNAse-free water. The RNA solution was stored at -20˚C.
RNA extraction by affinity column (SurePre Urine Exfoliated
Cell RNA Purification kit by Thermo Fisher). The untreated female urine sample (0.5 ml with the addition of 10 4 22RV1 cells) was centrifuged for 5 min (3,500 rpm, 4˚C); the supernatant was discarded. The sample was mixed with 500 µl TRK buffer, and mixed by pipetting. The sample was centrifuged for 3 min (≥14,000 rpm, ambient temperature). An equal volume of anhydrous ethanol was added and mixed by vortexing for 20 sec. The mixture was transferred to the affinity column, followed by centrifugation for 1 min (10,000 rpm, ambient temperature), and the effluent was discarded. RNA wash buffer I (300 µl) was added, followed by centrifugation for 1 min (10,000 rpm, ambient temperature), and the effluent was discarded. RNA wash buffer II (500 µl) was added, followed by centrifugation for 30 sec (10,000 rpm, ambient temperature), and the effluent was discarded; this step was repeated twice. The column was dried at an ambient temperature for 2 min. The column was transferred to a new 1.5 ml Ep tube, and 50 µl of DEPC-treated RNAse-free water was added to the column to elute RNA by resting for 2 min and centrifugation for 1 min (10,000 rpm, ambient temperature). The RNA solution was stored at -20˚C.
RNA extraction by Mag-Cap. Poly-T (T 25 ) functionalized magnetic beads (10-20 mg; NEB) were washed twice with 100 µl hybridization buffer (20 mM Tris, pH 7.5, 100 mM NaCl). The beads were incubated with 100 µl hybridization buffer that contained the capturer strand (1.5 µM, PCA3 capturer: 5'-ATC TGT TTT CCT GCC CAT CCT TTA AGT TTA (A) 30 ; PSA capturer: 5'-CGA ACT TGC GCA CAC ACG TCA TTG GAT TTA (A) 30 . The beads were then mixed with 100 µl hybridization buffer and 100 µl treated urine sample. The vial was shaken to ensure full mixing and the mixture was heated for 30 min (62±1˚C). The vial was cooled to ambient temperature for 30 min, and the magnetic beads were collected by magnetic attraction. The beads were washed for three times with 100 µl elution buffer (10 mM Tris, pH 7.5). The beads were mixed with 50 µl elution buffer, which were incubated at 70˚C for 5 min, and the solution was collected and subjected to RNA quantification.
RNA extraction by Mag-Bind. The procedure was the same as the Mag-Cap process only the capturer strand was not contained. where Ct-PCA3 is the Ct value during the amplification of the cDNA of PCA3; Ct-PSA is the Ct value during the amplification of the cDNA of PSA.
Statistical analysis. We used significance testing to compare the performance of Mag-Cap with the other methods. The power of PCA3 score for prostate cancer detection was evaluated using receiver operating characteristic (ROC) analysis. All statistical analysis was realized on SPSS (version 13.0). Comparison with a commercial kit. PCA3 in the 10 urine samples mentioned in the previous section was extracted by both Mag-Cap and a commercial magnetic bead-based RNA extraction kit (Mag-Bind mRNA kit; Omega Bio-Tek), and then quantified by qPCR. The results are shown in Fig. 3A . Medians of the Ct values of Mag-Cap and the Mag-Bind kit were 29.7 and 31.2, respectively. We also extracted and quantified PSA mRNA using the Mag-Bind kit. Median of the Ct values of 10 samples was 24.4, compared with 21.6 when mRNA was extracted using Mag-Cap (Fig. 3B) . The extraction yields of the two methods achieved significant difference for PCA3 and PSA extraction, respectively.
Results

Comparison of Mag
Clinical applications.
We assessed the values of our method for prostate cancer prediction and diagnosis retrospectively. We enrolled 52 male patients including 34 with diagnosed prostate cancer and 18 with BPH. Their urine samples were collected after prostate massage; PCA3 and PSA mRNA were extracted and quantified using Mag-Cap and real-time PCR, respectively. PCA3 scores were calculated as 1,000-fold of the ratio of PCA3 to PSA mRNA expression. The clinicopathological information and PCA3 scores of the patients enrolled are summarized in Tables I and II. Median values of the PCA3 scores for patients with prostate cancer and BPH were 53.5 and 17, respectively. ROC analysis was applied to assess the performance of the PCA3 score as a prostate-specific cancer marker. The curve was plotted in Fig. 4 (blue trace). For comparison, we also plotted the ROC curve of total PSA in Fig. 4 (green trace) . It was noted that the area under the curve (AUC) values for the PCA3 score and PSA were 0.831 and 0.655, respectively. A sensitivity of 82.4% and a specificity of 77.8% were obtained when the cut-off value for the PCA3 score was 28.5.
Discussion
Researchers have focused on improving methods with higher specificity for prostate cancer diagnosis, and thus reduce unnecessary prostate biopsy. Plasma PSA has been widely used as a diagnostic marker for prostate cancer, but also shares certain deficiencies. PSA is prostate tissue-specific rather than cancer-specific, thus conditions such as prostatitis, benign prostatic hyperplasia, acute urinary retention, digital rectal examination, and cystoscopy can interfere. In addition, prostate cancer patients are not always characterized by abnormal plasma PSA. Although PSA derivatives have been developed to increase the specificity and sensitivity, such as the fPSA/ tPSA ratio, PSA density, and PSA velocity, the outcome is still unsatisfactory.
PCA3, located in 9q21-22, was originally named differential display code 3 (DD3) in 1999. PCA3 is a non-coding RNA expressed inside the prostate gland. The PCA3 gene is overexpressed specifically in human prostate cancer cells, and is thus considered to be an independent and stable marker for prostate cancer. The quantification of urine PCA3 after prostate massage is a non-invasive detection method, which can significantly improve the sensitivity, specificity and accuracy of prostate cancer diagnosis, and reduce unnecessary prostate biopsy. However, the quantification of PCA3 remains difficult due to poor RNA stability and the lack of a purification method from complex matrix.
In the present study, we present a general method for RNA extraction (Mag-Cap). A key step for the extraction of nucleic acids using magnetic beads is to immobilize a capturing strand which is complimentary to the target strand on the beads. A straight forward way is covalent conjugation, which is timeand labor-consuming and not general. Each target strand requires unique functionalized magnetic beads, which significantly limits its clinical applications. Our method avoided the covalent immobilization of various capturing strands, which were instead immobilized through DNA hybridization. This avoided the conjugation of the magnetic beads with various strands and is general for DNA, RNA and even artificial nucleic acids such as PNA and LNA.
We compared Mag-Cap with phenol-chloroform extraction, affinity column and a commercial magnetic bead-based nucleic acid extraction kit using controlled samples. The extraction yield was quantified by real-time PCR after reverse transcription. Ct values of the Mag-Cap group were 3-6 cycles less than those extracted by phenol-chloroform extraction and affinity column, which indicated that the yield of Mag-Cap was at least 8 (23) times higher than the other two theoretically. We also found that Mag-Cap was more efficient than the commercial Mag-Bind kit. All RNA sequences were non-specifically extracted. Those unwanted nucleic acids might induce interference for further analysis.
We finally applied our method for PCA3 score measurement of clinical samples. The PCA3 score has been widely accepted as a more specific marker for prostate cancer screening. Irreproducibility and poor RNA extraction and detection limit the clinical applications of the PCA3 score (29) (30) (31) . We applied our method for PCA3 score testing retrospectively and assessed its value for prostate cancer diagnosis by ROC analysis. The AUC value was over 0.83, while AUC of the serum total PSA level was 0.66, which is consistent with previous studies (32) .
In this research, 2 cases of prostate cancer patients with serum tPSA <4 µg/l were both diagnosed with prostate cancer using the urinary PCA3 score when the cutoff value was 28.5, and 16 cases of prostate cancer patients with serum tPSA 4-10 µg/l. This indicates that the urinary PCA3 score contributed to the diagnosis of prostate cancer with normal serum tPSA or patients in the gray area. Cases (5 of 7) of BPH patients with serum tPSA >10 µg/l were excluded as prostate . ROC curves of the PCA3 score (blue) and total PSA (green) for prostate cancer diagnosis. ROC, receiver operating characteristics; PSA, prostate-specific antigen; PCA3, prostate cancer antigen 3.
cancer using the urinary PCA3 score method, which indicates that urinary PCA3 scores contribute to exclude prostate cancer in patients with elevated serum tPSA, thus reducing unnecessary prostate biopsy.
In conclusion, we present a novel RNA extraction technique based on magnetic beads while avoiding tedious covalent functionalization of the beads with nucleic acids. We found that the RNA extraction yields were higher than traditional phenolchloroform extraction, affinity column and a commercial RNA purification kit based on magnetic beads. We also report its application for PCA3 RNA detection. At the optimized condition, the sensitivity and specificity were 82.4 and 77.8%, respectively. However, this result was limited due to the small sample. Fortunately, this research is still ongoing, and further investigation is warranted for the application of the urinary PCA3 score in the diagnosis of prostate cancer.
